Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARES: Ibrexafungerp for Candida auris
NCT03363841Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Nov 2017
- Primary completion
- Apr 2023
- Modality
- Allosteric Modulators
- Countries
- 4
01
Overview
A Phase 3 trial of ibrexafungerp in candidiasis, candidemia, sponsored by SCYNEXIS, Inc.. Started Nov 2017; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
candidiasiscandidemia
Beyond the preview
Go deeper on NCT03363841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363841.